Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 11/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214471 | 0.86 | KDM1A (0.42) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL213799 | 0.85 | KDM1A (0.42) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL2735370 | 0.82 | KDM4E (0.41) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL214144 | 0.81 | KMT2A (0.46) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL2735431 | 0.81 | KMT2A (0.46) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL216261 | 0.80 | ALDH1A1 (0.41) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL216947 | 0.80 | SMN1; SMN2 (0.40) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL214698 | 0.79 | KMT2A (0.46) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL2735373 | 0.78 | ALDH1A1 (0.47) | TOP2AHSP90AB1ALDH1A1KMT2AMAPT | |
| SCHEMBL216248 | 0.78 | RAB9A (0.41) | ALDH1A1KMT2AMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | TOP2A 1957/4885HSP90AB1 1319/4885ALDH1A1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.